Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Risankizumab versus placebo in moderate to severe chronic plaque psoriasis
2014-005102-38Phase 3Completed
- Sponsor
- Boehringer Ingelheim
- Start
- Dec 2015
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in psoriasis comparing Risankizumab with Placebo (2 arms). Primary endpoint: PASI90 at week 16. Started Dec 2015; status: completed.
02
Drugs
risankizumab
03
Conditions
psoriasis
Beyond the preview
Go deeper on 2014-005102-38.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2014-005102-38.